{"id":7944,"date":"2025-07-16T15:41:40","date_gmt":"2025-07-16T12:41:40","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=7944"},"modified":"2025-07-16T15:41:40","modified_gmt":"2025-07-16T12:41:40","slug":"ai-enhanced-echocardiography-for-cardiac-amyloidosis-detection-july-9-2025","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/ai-enhanced-echocardiography-for-cardiac-amyloidosis-detection-july-9-2025\/","title":{"rendered":"AI-Enhanced Echocardiography for Cardiac Amyloidosis Detection \u2013 July 9, 2025."},"content":{"rendered":"
AI-Enhanced Echocardiography for Cardiac Amyloidosis Detection \u2013 July 9, 2025.<\/div>\n
<\/div>\n
The findings were published in full European Heart Journal.<\/div>\n
<\/div>\n
1. Innovation Overview:<\/span><\/div>\n
\u2022 Mayo Clinic and Ultromics developed the first AI model designed specifically for screening cardiac amyloidosis using echocardiography.<\/span><\/div>\n
\u2022 Validated in a clinical trial with >2,600 patients across a multi-ethnic international population.<\/span><\/div>\n
2. Diagnostic Accuracy:<\/span><\/div>\n
\u2022 Sensitivity: 85% (correctly identifying those with the disease)<\/span><\/div>\n
\u2022 Specificity: 93% (correctly identifying those without the disease)<\/span><\/div>\n
\u2022 Effective using a single echocardiography videoclip<\/span><\/div>\n
\u2022 Outperformed traditional clinical scoring systems:<\/span><\/div>\n
\u2022 TTR cardiac amyloidosis score<\/span><\/div>\n
\u2022 Increased wall thickness score<\/span><\/div>\n
3. Amyloidosis Subtypes:<\/span><\/div>\n
\u2022 Successfully detected:<\/span><\/div>\n
\u2022 AL amyloidosis: 84% sensitivity<\/span><\/div>\n
\u2022 ATTR wild-type (wtATTR): 85%<\/span><\/div>\n
\u2022 ATTR hereditary (hATTR): 86%<\/span><\/div>\n
4. Comparison with Traditional Methods:<\/span><\/div>\n
\u2022 Conventional diagnosis relies on:<\/span><\/div>\n
\u2022 ECG + Echo<\/span><\/div>\n
\u2022 Red-flag feature recognition \u2192 MRI, Tc-PYP scan, or biopsy<\/span><\/div>\n
\u2022 AI model improves early detection and supports non-invasive triaging.<\/span><\/div>\n
5. Clinical Significance:<\/span><\/div>\n
\u2022 Cardiac amyloidosis is often underdiagnosed due to nonspecific symptoms and imaging features.<\/span><\/div>\n
\u2022 Early detection is essential since new drug therapies (e.g., tafamidis) can slow but not reverse disease progression.<\/span><\/div>\n
\u2022 Estimated 15% of HFpEF patients may have underlying cardiac amyloidosis.<\/span><\/div>\n
6. Integration & Use:<\/span><\/div>\n
\u2022 AI model is FDA-cleared<\/span><\/div>\n
\u2022 Interfaces directly with PACS echo systems<\/span><\/div>\n
\u2022 Currently used in multiple U.S. centers, including Mayo Clinic<\/span><\/div>\n
7. Expert Perspective:<\/span><\/div>\n
\u2022 Dr. Patricia A. Pellikka:<\/span><\/div>\n
\u2022 Lead investigator and Mayo Clinic cardiologist<\/span><\/div>\n
\u2022 Emphasized the model\u2019s breakthrough value in identifying amyloid early<\/span><\/div>\n
\u2022 Expressed optimism about incorporating the tool into clinical practice<\/span><\/div>\n
8. Background & Future:<\/span><\/div>\n
\u2022 Builds on Mayo and Ultromics\u2019 prior AI work (e.g., FDA-cleared HFpEF detection tool in 2022)<\/span><\/div>\n
\u2022 Part of a broader trend toward AI-guided echo diagnostics for complex cardiomyopathies<\/span><\/div>\n
<\/div>\n
https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehaf387\/8193027<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

AI-Enhanced Echocardiography for Cardiac Amyloidosis Detection \u2013 July 9, 2025. The findings were published in full European Heart Journal. 1. Innovation Overview: \u2022 Mayo Clinic and Ultromics developed the first AI model designed specifically for screening cardiac amyloidosis using echocardiography. \u2022 Validated in a clinical trial with >2,600 patients across a multi-ethnic international population. 2. […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7944","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7944","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=7944"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7944\/revisions"}],"predecessor-version":[{"id":7945,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7944\/revisions\/7945"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=7944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=7944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=7944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}